220 related articles for article (PubMed ID: 26790612)
1. Exome sequencing reveals recurrent REV3L mutations in cisplatin-resistant squamous cell carcinoma of head and neck.
Huang KK; Jang KW; Kim S; Kim HS; Kim SM; Kwon HJ; Kim HR; Yun HJ; Ahn MJ; Park KU; Ramnarayanan K; McPherson JR; Zhang S; Rhee JK; Vettore AL; Das K; Ishimoto T; Kim JH; Koh YW; Kim SH; Choi EC; Teh BT; Rozen SG; Kim TM; Tan P; Cho BC
Sci Rep; 2016 Jan; 6():19552. PubMed ID: 26790612
[TBL] [Abstract][Full Text] [Related]
2. Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.
Kim HS; Kwon HJ; Jung I; Yun MR; Ahn MJ; Kang BW; Sun JM; Kim SB; Yoon DH; Park KU; Lee SH; Koh YW; Kim SH; Choi EC; Koo DH; Sohn JH; Kim B; Kwon NJ; Yun HJ; Lee MG; Lee JH; Kim TM; Kim HR; Kim JH; Paik S; Cho BC
Clin Cancer Res; 2015 Feb; 21(3):544-52. PubMed ID: 25424851
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001).
Prawira A; Brana-Garcia I; Spreafico A; Hope A; Waldron J; Razak AR; Chen EX; Jang R; O'Sullivan B; Giuliani M; Bayley A; Cho J; Wang L; Perez-Ordonez B; Weinreb I; Siu LL; Hansen AR
Invest New Drugs; 2016 Oct; 34(5):575-83. PubMed ID: 27289242
[TBL] [Abstract][Full Text] [Related]
4. Genetic and expression profiles of squamous cell carcinoma of the head and neck correlate with cisplatin sensitivity and resistance in cell lines and patients.
Akervall J; Guo X; Qian CN; Schoumans J; Leeser B; Kort E; Cole A; Resau J; Bradford C; Carey T; Wennerberg J; Anderson H; Tennvall J; Teh BT
Clin Cancer Res; 2004 Dec; 10(24):8204-13. PubMed ID: 15623595
[TBL] [Abstract][Full Text] [Related]
5. Pre-clinical characterization of Dacomitinib (PF-00299804), an irreversible pan-ErbB inhibitor, combined with ionizing radiation for head and neck squamous cell carcinoma.
Williams JP; Kim I; Ito E; Shi W; Yue S; Siu LL; Waldron J; O'Sullivan B; Yip KW; Liu FF
PLoS One; 2014; 9(5):e98557. PubMed ID: 24853121
[TBL] [Abstract][Full Text] [Related]
6. REV3L, the catalytic subunit of DNA polymerase ζ, is involved in the progression and chemoresistance of esophageal squamous cell carcinoma.
Zhu X; Zou S; Zhou J; Zhu H; Zhang S; Shang Z; Ding WQ; Wu J; Chen Y
Oncol Rep; 2016 Mar; 35(3):1664-70. PubMed ID: 26752104
[TBL] [Abstract][Full Text] [Related]
7. REV3L modulates cisplatin sensitivity of non-small cell lung cancer H1299 cells.
Wang W; Sheng W; Yu C; Cao J; Zhou J; Wu J; Zhang H; Zhang S
Oncol Rep; 2015 Sep; 34(3):1460-8. PubMed ID: 26165320
[TBL] [Abstract][Full Text] [Related]
8. The mutational spectrum of squamous-cell carcinoma of the head and neck: targetable genetic events and clinical impact.
Mountzios G; Rampias T; Psyrri A
Ann Oncol; 2014 Oct; 25(10):1889-1900. PubMed ID: 24718888
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA‑29a enhances cisplatin sensitivity in non‑small cell lung cancer through the regulation of REV3L.
Chen X; Zhu H; Ye W; Cui Y; Chen M
Mol Med Rep; 2019 Feb; 19(2):831-840. PubMed ID: 30535450
[TBL] [Abstract][Full Text] [Related]
10. Over-expression of BAG-1 in head and neck squamous cell carcinomas (HNSCC) is associated with cisplatin-resistance.
Liu S; Ren B; Gao H; Liao S; Zhai YX; Li S; Su XJ; Jin P; Stroncek D; Xu Z; Zeng Q; Li Y
J Transl Med; 2017 Sep; 15(1):189. PubMed ID: 28877725
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic assessment of dacomitinib (pan-HER tyrosine kinase inhibitor) in patients with locally advanced head and neck squamous cell carcinoma (LA SCCHN) following administration through a gastrostomy feeding tube (GT).
Chiu JW; Chan K; Chen EX; Siu LL; Abdul Razak AR
Invest New Drugs; 2015 Aug; 33(4):895-900. PubMed ID: 25937431
[TBL] [Abstract][Full Text] [Related]
12. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
Caponigro F; Di Gennaro E; Ionna F; Longo F; Aversa C; Pavone E; Maglione MG; Di Marzo M; Muto P; Cavalcanti E; Petrillo A; Sandomenico F; Maiolino P; D'Aniello R; Botti G; De Cecio R; Losito NS; Scala S; Trotta A; Zotti AI; Bruzzese F; Daponte A; Calogero E; Montano M; Pontone M; De Feo G; Perri F; Budillon A
BMC Cancer; 2016 Nov; 16(1):918. PubMed ID: 27884140
[TBL] [Abstract][Full Text] [Related]
13. Decreased STAT1 expression by promoter methylation in squamous cell carcinogenesis.
Xi S; Dyer KF; Kimak M; Zhang Q; Gooding WE; Chaillet JR; Chai RL; Ferrell RE; Zamboni B; Hunt J; Grandis JR
J Natl Cancer Inst; 2006 Feb; 98(3):181-9. PubMed ID: 16449678
[TBL] [Abstract][Full Text] [Related]
14. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy.
Quintela-Fandino M; Hitt R; Medina PP; Gamarra S; Manso L; Cortes-Funes H; Sanchez-Cespedes M
J Clin Oncol; 2006 Sep; 24(26):4333-9. PubMed ID: 16896002
[TBL] [Abstract][Full Text] [Related]
15. TRIP13 promotes error-prone nonhomologous end joining and induces chemoresistance in head and neck cancer.
Banerjee R; Russo N; Liu M; Basrur V; Bellile E; Palanisamy N; Scanlon CS; van Tubergen E; Inglehart RC; Metwally T; Mani RS; Yocum A; Nyati MK; Castilho RM; Varambally S; Chinnaiyan AM; D'Silva NJ
Nat Commun; 2014 Jul; 5():4527. PubMed ID: 25078033
[TBL] [Abstract][Full Text] [Related]
16. Cancer stem cell mediated acquired chemoresistance in head and neck cancer can be abrogated by aldehyde dehydrogenase 1 A1 inhibition.
Kulsum S; Sudheendra HV; Pandian R; Ravindra DR; Siddappa G; R N; Chevour P; Ramachandran B; Sagar M; Jayaprakash A; Mehta A; Kekatpure V; Hedne N; Kuriakose MA; Suresh A
Mol Carcinog; 2017 Feb; 56(2):694-711. PubMed ID: 27380877
[TBL] [Abstract][Full Text] [Related]
17. Multilayered Omics-Based Analysis of a Head and Neck Cancer Model of Cisplatin Resistance Reveals Intratumoral Heterogeneity and Treatment-Induced Clonal Selection.
Niehr F; Eder T; Pilz T; Konschak R; Treue D; Klauschen F; Bockmayr M; Türkmen S; Jöhrens K; Budach V; Tinhofer I
Clin Cancer Res; 2018 Jan; 24(1):158-168. PubMed ID: 29061642
[No Abstract] [Full Text] [Related]
18. Targeted next-generation sequencing identifies molecular subgroups in squamous cell carcinoma of the head and neck with distinct outcome after concurrent chemoradiation.
Tinhofer I; Stenzinger A; Eder T; Konschak R; Niehr F; Endris V; Distel L; Hautmann MG; Mandic R; Stromberger C; Weichert W; Budach V
Ann Oncol; 2016 Dec; 27(12):2262-2268. PubMed ID: 27681865
[TBL] [Abstract][Full Text] [Related]
19. Expression of DNA translesion synthesis polymerase η in head and neck squamous cell cancer predicts resistance to gemcitabine and cisplatin-based chemotherapy.
Zhou W; Chen YW; Liu X; Chu P; Loria S; Wang Y; Yen Y; Chou KM
PLoS One; 2013; 8(12):e83978. PubMed ID: 24376779
[TBL] [Abstract][Full Text] [Related]
20. Mutation of p53 in head and neck squamous cell carcinoma correlates with Bcl-2 expression and increased susceptibility to cisplatin-induced apoptosis.
Andrews GA; Xi S; Pomerantz RG; Lin CJ; Gooding WE; Wentzel AL; Wu L; Sidransky D; Grandis JR
Head Neck; 2004 Oct; 26(10):870-7. PubMed ID: 15390206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
